Bristol Myers Beats Pomalyst Antitrust Suit Alleging IP Fraud
Bristol Myers Squibb (BMS) has successfully defended itself against a high-profile antitrust lawsuit that accused the pharmaceutical giant of engaging in intellectual property (IP) fraud to delay generic competition f...